ClinicalTrials.govpublic full text
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
acute myeloid leukemia, myelodysplastic syndrome, recurrent acute myeloid leukemia, refractory acute myeloid leukemia, interventional, phase1, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 848562
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.